Related references
Note: Only part of the references are listed.A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration
A. J. M. Beijers et al.
SUPPORTIVE CARE IN CANCER (2014)
Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review
Floortje Mols et al.
SUPPORTIVE CARE IN CANCER (2014)
Clinical pattern and associations of oxaliplatin acute neurotoxicity
Andreas A. Argyriou et al.
CANCER (2013)
Diminishing differences in treatment between patients with colorectal cancer with and without diabetes: a population-based study
M. M. J. Zanders et al.
DIABETIC MEDICINE (2013)
Chemotherapy-Induced Neuropathy and Its Association With Quality of Life Among 2-to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry
Floortje Mols et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The NaV1.7 sodium channel: from molecule to man
Sulayman D. Dib-Hajj et al.
NATURE REVIEWS NEUROSCIENCE (2013)
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
Thierry Andre et al.
CURRENT COLORECTAL CANCER REPORTS (2013)
Gain of function NaV1.7 mutations in idiopathic small fiber neuropathy
Catharina G. Faber et al.
ANNALS OF NEUROLOGY (2012)
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients
A. A. Argyriou et al.
ANNALS OF ONCOLOGY (2012)
Gain-of-function Nav1.8 mutations in painful neuropathy
Catharina G. Faber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: Scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts
Lonneke V. van de Poll-Franse et al.
EUROPEAN JOURNAL OF CANCER (2011)
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
Michel Ducreux et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility
Susanna B. Park et al.
ONCOLOGIST (2011)
Dose Effects of Oxaliplatin on Persistent and Transient Na+ Conductances and the Development of Neurotoxicity
Susanna B. Park et al.
PLOS ONE (2011)
Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
D. J. Storey et al.
ANNALS OF ONCOLOGY (2010)
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07
Stephanie R. Land et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients
Hans-Joachim Schmoll et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20
TJ Postma et al.
EUROPEAN JOURNAL OF CANCER (2005)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat
G Cavaletti et al.
EUROPEAN JOURNAL OF CANCER (2001)
The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons
H Adelsberger et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
